Alphatec to renegotiate Scient’X deal
This article was originally published in The Gray Sheet
Executive Summary
Recent Alphatec stock price slump will require the spinal device maker to renegotiate its planned purchase of artificial disc developer Scient'X, the company says Nov. 7. First announced Sept. 27 and valued at about $180 mil., the acquisition is based primarily on a stock-swap, with a small cash component (1"The Gray Sheet" Oct. 2, 2006, p. 8). The stock decline is due in part to a July sales force reorganization that resulted in lower than expected third quarter sales. An Oct. 6 Q3 results preview was followed by the departure of CFO Stephen Dixon Oct. 19. On Nov. 10, Alphatec stock closed at $2.98, down 54% from its Sept. 27 close of $6.50...
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.